Exchange: NASDAQ·Updated 07:58 PM EST

AZN News

News
all
press releases
FDA Grants Priority Tag to AZN's BLA Filing for Gastric Cancer Drug
AstraZeneca gains FDA priority review for its Sone-Ve cancer drug application, with a regulatory decision expected in Q2 2027.
Zacks
FDA Grants Priority Tag to AZN's BLA Filing for Gastric Cancer Drug
AstraZeneca gains FDA priority review for its Sone-Ve cancer drug application, with a regulatory decision expected in Q2 2027.
Zacks
More News
USS Investment Management Ltd acquired a new position in shares of AstraZeneca Plc (NYSE:AZN - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 255,043 shares of the company's stock...
MarketBeat
Edmond DE Rothschild Holding S.A. bought a new position in shares of AstraZeneca Plc (NYSE:AZN - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 454,062 shares of the company's st...
MarketBeat
Taiwan Semiconductor Manufacturing, Applied Materials, AstraZeneca, ASE Technology, Phillips 66, Flex, and Honeywell Aerospace are the seven Manufacturing stocks to watch today, according to MarketBeat's stock screener tool. Manufacturing stocks are shares of companies that make physical goods, suc...
MarketBeat
AstraZeneca commits $200 million to Tempus AI in a master services agreement renewal through 2031, while William Blair maintains a Market Perform rating.read more...
Benzinga
Rhythm Pharma: Is AstraZeneca/Eli Lilly's Bidding War For Real? Don't Rule It Out...
SeekingAlpha
AstraZeneca, Linde, Eaton, Franklin and BV Financial are included in this Analyst Blog.
Zacks
Taiwan Semiconductor Manufacturing, Applied Materials, Phillips 66, ASE Technology, AstraZeneca, Johnson Controls International, and Flex are the seven Manufacturing stocks to watch today, according to MarketBeat's stock screener tool. Manufacturing stocks are shares of companies that make physical...
MarketBeat
AZN's 16 blockbuster drugs, strong oncology sales and pipeline opportunities support its $80B revenue target, despite generic pressure and clinical setbacks.
Zacks
AZN secures US and EU approval for Klygefa, a once-weekly gMG treatment that offers patients greater convenience.
Zacks

Advertisement|Remove ads.